Selected research
Market Analysis & Forecast
Global mRNA Platform Market Analysis and Forecast 2026-2032
Market perspective
The global mRNA Platform market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for mRNA Platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for mRNA Platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for mRNA Platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for mRNA Platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of mRNA Platform include Arcturus Therapeutic, Argos Therapeutics, BioNTec, CureVac, Etherna, Ethris, Translate Bio, GlaxoSmithKline and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for mRNA Platform, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of mRNA Platform, also provides the revenue of main regions and countries. Of the upcoming market potential for mRNA Platform, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the mRNA Platform revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global mRNA Platform market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for mRNA Platform revenue, projected growth trends, production technology, application and end-user industry.
mRNA Platform Segment by Company
Arcturus Therapeutic
Argos Therapeutics
BioNTec
CureVac
Etherna
Ethris
Translate Bio
GlaxoSmithKline
Pfizer
mRNA Platform Segment by Type
Infectious Disease Vaccines
Cancer Vaccines
mRNA Platform Segment by Application
Infectious Disease
Cancer
mRNA Platform Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Platform.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of mRNA Platform in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of mRNA Platform company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, mRNA Platform revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Infectious Disease Vaccines
- Cancer Vaccines
Applications
- Infectious Disease
- Cancer
Companies covered
- Arcturus Therapeutic
- Argos Therapeutics
- BioNTec
- CureVac
- Etherna
- Ethris
- Translate Bio
- GlaxoSmithKline
- Pfizer
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 mRNA Platform Market by Type
- 1.2.1 Global mRNA Platform Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Infectious Disease Vaccines
- 1.2.3 Cancer Vaccines
- 1.3 mRNA Platform Market by Application
- 1.3.1 Global mRNA Platform Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Infectious Disease
- 1.3.3 Cancer
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 mRNA Platform Market Dynamics
- 2.1 mRNA Platform Industry Trends
- 2.2 mRNA Platform Industry Drivers
- 2.3 mRNA Platform Industry Opportunities and Challenges
- 2.4 mRNA Platform Industry Restraints
3 Global Growth Perspective
- 3.1 Global mRNA Platform Market Perspective (2021-2032)
- 3.2 Global mRNA Platform Growth Trends by Region
- 3.2.1 Global mRNA Platform Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global mRNA Platform Market Size by Region (2021-2026)
- 3.2.3 Global mRNA Platform Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global mRNA Platform Revenue by Players
- 4.1.1 Global mRNA Platform Revenue by Players (2021-2026)
- 4.1.2 Global mRNA Platform Revenue Market Share by Players (2021-2026)
- 4.1.3 Global mRNA Platform Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global mRNA Platform Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global mRNA Platform Key Players Headquarters & Area Served
- 4.4 Global mRNA Platform Players, Product Type & Application
- 4.5 Global mRNA Platform Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global mRNA Platform Market CR5 and HHI
- 4.6.3 2025 mRNA Platform Tier 1, Tier 2, and Tier 3
5 mRNA Platform Market Size by Type
- 5.1 Global mRNA Platform Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global mRNA Platform Revenue by Type (2021-2032)
- 5.3 Global mRNA Platform Revenue Market Share by Type (2021-2032)
6 mRNA Platform Market Size by Application
- 6.1 Global mRNA Platform Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global mRNA Platform Revenue by Application (2021-2032)
- 6.3 Global mRNA Platform Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Arcturus Therapeutic
- 7.1.1 Arcturus Therapeutic Company Information
- 7.1.2 Arcturus Therapeutic Business Overview
- 7.1.3 Arcturus Therapeutic mRNA Platform Revenue and Gross Margin (2021-2026)
- 7.1.4 Arcturus Therapeutic mRNA Platform Product Portfolio
- 7.1.5 Arcturus Therapeutic Recent Developments
- 7.2 Argos Therapeutics
- 7.2.1 Argos Therapeutics Company Information
- 7.2.2 Argos Therapeutics Business Overview
- 7.2.3 Argos Therapeutics mRNA Platform Revenue and Gross Margin (2021-2026)
- 7.2.4 Argos Therapeutics mRNA Platform Product Portfolio
- 7.2.5 Argos Therapeutics Recent Developments
- 7.3 BioNTec
- 7.3.1 BioNTec Company Information
- 7.3.2 BioNTec Business Overview
- 7.3.3 BioNTec mRNA Platform Revenue and Gross Margin (2021-2026)
- 7.3.4 BioNTec mRNA Platform Product Portfolio
- 7.3.5 BioNTec Recent Developments
- 7.4 CureVac
- 7.4.1 CureVac Company Information
- 7.4.2 CureVac Business Overview
- 7.4.3 CureVac mRNA Platform Revenue and Gross Margin (2021-2026)
- 7.4.4 CureVac mRNA Platform Product Portfolio
- 7.4.5 CureVac Recent Developments
- 7.5 Etherna
- 7.5.1 Etherna Company Information
- 7.5.2 Etherna Business Overview
- 7.5.3 Etherna mRNA Platform Revenue and Gross Margin (2021-2026)
- 7.5.4 Etherna mRNA Platform Product Portfolio
- 7.5.5 Etherna Recent Developments
- 7.6 Ethris
- 7.6.1 Ethris Company Information
- 7.6.2 Ethris Business Overview
- 7.6.3 Ethris mRNA Platform Revenue and Gross Margin (2021-2026)
- 7.6.4 Ethris mRNA Platform Product Portfolio
- 7.6.5 Ethris Recent Developments
- 7.7 Translate Bio
- 7.7.1 Translate Bio Company Information
- 7.7.2 Translate Bio Business Overview
- 7.7.3 Translate Bio mRNA Platform Revenue and Gross Margin (2021-2026)
- 7.7.4 Translate Bio mRNA Platform Product Portfolio
- 7.7.5 Translate Bio Recent Developments
- 7.8 GlaxoSmithKline
- 7.8.1 GlaxoSmithKline Company Information
- 7.8.2 GlaxoSmithKline Business Overview
- 7.8.3 GlaxoSmithKline mRNA Platform Revenue and Gross Margin (2021-2026)
- 7.8.4 GlaxoSmithKline mRNA Platform Product Portfolio
- 7.8.5 GlaxoSmithKline Recent Developments
- 7.9 Pfizer
- 7.9.1 Pfizer Company Information
- 7.9.2 Pfizer Business Overview
- 7.9.3 Pfizer mRNA Platform Revenue and Gross Margin (2021-2026)
- 7.9.4 Pfizer mRNA Platform Product Portfolio
- 7.9.5 Pfizer Recent Developments
8 North America
- 8.1 North America mRNA Platform Revenue (2021-2032)
- 8.2 North America mRNA Platform Revenue by Type (2021-2032)
- 8.2.1 North America mRNA Platform Revenue by Type (2021-2026)
- 8.2.2 North America mRNA Platform Revenue by Type (2027-2032)
- 8.3 North America mRNA Platform Revenue Share by Type (2021-2032)
- 8.4 North America mRNA Platform Revenue by Application (2021-2032)
- 8.4.1 North America mRNA Platform Revenue by Application (2021-2026)
- 8.4.2 North America mRNA Platform Revenue by Application (2027-2032)
- 8.5 North America mRNA Platform Revenue Share by Application (2021-2032)
- 8.6 North America mRNA Platform Revenue by Country
- 8.6.1 North America mRNA Platform Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America mRNA Platform Revenue by Country (2021-2026)
- 8.6.3 North America mRNA Platform Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe mRNA Platform Revenue (2021-2032)
- 9.2 Europe mRNA Platform Revenue by Type (2021-2032)
- 9.2.1 Europe mRNA Platform Revenue by Type (2021-2026)
- 9.2.2 Europe mRNA Platform Revenue by Type (2027-2032)
- 9.3 Europe mRNA Platform Revenue Share by Type (2021-2032)
- 9.4 Europe mRNA Platform Revenue by Application (2021-2032)
- 9.4.1 Europe mRNA Platform Revenue by Application (2021-2026)
- 9.4.2 Europe mRNA Platform Revenue by Application (2027-2032)
- 9.5 Europe mRNA Platform Revenue Share by Application (2021-2032)
- 9.6 Europe mRNA Platform Revenue by Country
- 9.6.1 Europe mRNA Platform Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe mRNA Platform Revenue by Country (2021-2026)
- 9.6.3 Europe mRNA Platform Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
10 China
- 10.1 China mRNA Platform Revenue (2021-2032)
- 10.2 China mRNA Platform Revenue by Type (2021-2032)
- 10.2.1 China mRNA Platform Revenue by Type (2021-2026)
- 10.2.2 China mRNA Platform Revenue by Type (2027-2032)
- 10.3 China mRNA Platform Revenue Share by Type (2021-2032)
- 10.4 China mRNA Platform Revenue by Application (2021-2032)
- 10.4.1 China mRNA Platform Revenue by Application (2021-2026)
- 10.4.2 China mRNA Platform Revenue by Application (2027-2032)
- 10.5 China mRNA Platform Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia mRNA Platform Revenue (2021-2032)
- 11.2 Asia mRNA Platform Revenue by Type (2021-2032)
- 11.2.1 Asia mRNA Platform Revenue by Type (2021-2026)
- 11.2.2 Asia mRNA Platform Revenue by Type (2027-2032)
- 11.3 Asia mRNA Platform Revenue Share by Type (2021-2032)
- 11.4 Asia mRNA Platform Revenue by Application (2021-2032)
- 11.4.1 Asia mRNA Platform Revenue by Application (2021-2026)
- 11.4.2 Asia mRNA Platform Revenue by Application (2027-2032)
- 11.5 Asia mRNA Platform Revenue Share by Application (2021-2032)
- 11.6 Asia mRNA Platform Revenue by Country
- 11.6.1 Asia mRNA Platform Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia mRNA Platform Revenue by Country (2021-2026)
- 11.6.3 Asia mRNA Platform Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA mRNA Platform Revenue (2021-2032)
- 12.2 SAMEA mRNA Platform Revenue by Type (2021-2032)
- 12.2.1 SAMEA mRNA Platform Revenue by Type (2021-2026)
- 12.2.2 SAMEA mRNA Platform Revenue by Type (2027-2032)
- 12.3 SAMEA mRNA Platform Revenue Share by Type (2021-2032)
- 12.4 SAMEA mRNA Platform Revenue by Application (2021-2032)
- 12.4.1 SAMEA mRNA Platform Revenue by Application (2021-2026)
- 12.4.2 SAMEA mRNA Platform Revenue by Application (2027-2032)
- 12.5 SAMEA mRNA Platform Revenue Share by Application (2021-2032)
- 12.6 SAMEA mRNA Platform Revenue by Country
- 12.6.1 SAMEA mRNA Platform Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA mRNA Platform Revenue by Country (2021-2026)
- 12.6.3 SAMEA mRNA Platform Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst